The rate of such reactions for coronavirus vaccine is 11.1 cases per million doses given, while it is 1.3 per million for flu vaccines
As vaccination efforts against coronavirus continue across the US, researchers are looking closely at reports of severe allergic reactions to the shot. During December 14-23, 2020, 21 cases of anaphylaxis-a severe, life-threatening allergic reaction that may occur after vaccination, with onset typically within minutes to hours-were reported after administration of 1,893,360 first doses of the Pfizer-BioNTech Covid-19 shot, reveals an analysis by the US Centers for Disease Control and Prevention (CDC). This implies that such reactions are occurring at a rate of 11.1 cases per 1 million doses administered. For comparison, in the case of flu vaccines, such reactions occur at an estimated rate of 1.3 per 1 million doses, suggests the agency.
According to Dr Nancy Messonnier, director of the CDC’s National Center for Immunization and Respiratory Diseases, while mathematically one could say that is about 10 times the amount, but that “misses the point” because it is still “exceedingly rare,” and that is the message the American public should get from this.
“The anaphylaxis rate for Covid-19 vaccines may seem high compared to flu vaccines, but I want to reassure you this is still a rare outcome. Additionally, we have been adapting our recommendations as we learn more. Anyone who has had an immediate reaction to the first dose should not receive the second dose. Anyone with a history of an immediate allergic reaction to an injectable vaccine and people with a history of anaphylaxis due to any cause should be observed for 30 minutes after vaccination,” she explains.
Dr Messonnier emphasizes that the agency’s vaccine safety systems have not picked up any worrisome signals, which means that right now, the known and potential benefits of the current Covid-19 vaccines outweigh the known and potential risks of getting Covid-19. That does not mean, however, that one would not see potential serious health events in the future, she notes.
“We’re in the setting of 2,000 Covid-19 deaths per day, If you make that comparison, I think that you can sort of anticipate that I would say it’s still a good value proposition for someone to get vaccinated. Their risk from Covid-19 and poor outcomes from it is still more than their risk of severe outcome from the vaccine. Fortunately, we know how to treat anaphylaxis, and we have put provisions in place to ensure that at immunization sites, the folks administering the vaccine are ready to treat anaphylaxis,” says Dr Messonnier.
The CDC and the US Food and Drug Administration (FDA) are reviewing all serious adverse event reports with. Brinkwire Brief News.